Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16941093 | 0.90 | NAMPT (0.56) | CDK4CCND1NAMPTHDAC6MEN1 | |
| SCHEMBL25702642 | 0.85 | CDK4 (0.48) | CDK4CCND1NAMPTHDAC6HDAC1 | |
| SCHEMBL11210960 | 0.84 | HDAC6 (0.59) | CDK4CCND1HDAC6MEN1KMT2A | |
| SCHEMBL8641718 | 0.84 | HDAC6 (0.59) | CDK4CCND1HDAC6MEN1KMT2A | |
| SCHEMBL23696645 | 0.84 | HPGD (0.48) | CDK4CCND1NAMPTHDAC6MLYCD | |
| SCHEMBL24847487 | 0.83 | MEN1 (0.45) | NAMPTHDAC6MEN1KMT2AMLYCD | |
| SCHEMBL1003650 | 0.82 | NAMPT (0.55) | CDK4CCND1NAMPTHDAC6MEN1 | |
| SCHEMBL17317100 | 0.82 | CDK4 (0.46) | CDK4CCND1HDAC6NPC1MLYCD | |
| SCHEMBL11210779 | 0.82 | KMT2A (0.56) | CDK4CCND1HDAC6MEN1KMT2A | |
| SCHEMBL1002785 | 0.81 | NAMPT (0.56) | CDK4CCND1NAMPTHDAC6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2025-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | WNT1, XPOT, CTNNBL1 | CDK4 533/4885CCND1 730/4885NAMPT 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.